Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Akeso Closes $150 Million Series D for Antibody Development

publication date: Nov 4, 2019

Akeso Biopharma, a Zhongshan antibody company, closed a $150 million Series D round of financing led by Loyal Valley Capital, a private equity firm, and Sino Biopharm. AkesoBio is developing a portfolio of 18 mAbs that are in either CMC or clinical stages of development for indications in oncology, inflammation, autoimmune and cardiovascular diseases. The company has filed seven IND applications in China, and it has begun clinical trials on two of them. One year ago, Akeso completed a Series C led by Ally Bridge, though the company did not disclose the size of the earlier round. More details....

Stock Symbols: (HK:1177)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.